The DOI matches its Crossref record.
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Open accessAbstract
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology Controlled studies in polycythemia vera (PV) have demonstrated the value of aggressive phlebotomy, aspirin, and cytoreductive therapy in preventing thrombotic complications.[1][2][3] In the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) prospective study of 1638 patients diagnosed by using criteria from the Polycythemia Vera Study Group, risk factors for all thromboses were age older than 65 years and prior thrombotic events.4 However, diagnosis criteria for PV have since undergone substantial revision in the World Health Organization system for disease classification, with special emphasis on bone marrow morphology and JAK2 mutational status. 5 Accordingly, this study includes 1545 patients with strictly World Health Organization-defined PV who were diagnosed and followed up in 7 centers in Italy, Austria, and the United States that belong to the International Working Group for Myeloproliferative Neoplasms.The study was approved by the institutional review board at each institution.Objectives were to ( 1) describe the rate of thrombosis, (2) report the sites and frequency of recurrences after a first arterial or venous event, and (3) identify risk factors for arterial vs venous thrombosis.The characteristics of the cohort recruited at diagnosis (Table 1) reflect the heterogeneity of epidemiologic and clinical features that are found in the routine clinical practice of diagnosing PV.Arterial and venous thrombosis history before or at diagnosis was documented in 246 (16%) and 114 (7.4%) patients, respectively.The frequencies of arterial and venous thrombosis were lower than those recorded in the ECLAP study 4 (27% and 11%, respectively) but comparable to those reported in the recent Cyto-PV study 2 (arterial 17%, venous 12%).Major hemorrhage before or at diagnosis was reported in 4.5% of patients in this study vs 8% in ECLAP and 1.7% in Cyto-PV cohorts.The prevalence of hypertension, hyperlipidemia, diabetes, and tobacco use was similar to that reported in the ECLAP and Cyto-PV studies.Median follow-up was 6.9 years, and treatment included aspirin (84%) and cytoreductive agents (73%), in addition to phlebotomy (Table 1).Postdiagnosis total major thrombosis rate was 2.62% patients per year, lower than that reported in the ECLAP trial (4.4% patients per year) but comparable to the rate in the Cyto-PV study (2.7% patients per year) in which management of cardiovascular risk factors was more intensive than in the ECLAP study.Arterial or venous thrombosis occurred in 184 (12%; rate: 1.59% patients per year) and 137 (9%; rate: 1.05% patients per year) patients, respectively.In addition, in 75% of the patients, arterial events were associated with subsequent arterial events, and in the remaining 25%, they were associated with venous thrombosis including splanchnic vein events.Conversely, in patients with prior venous events, 61% had venous recurrences and 39% had arterial recurrences.In multivariable analysis, previous arterial event (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.2 to 2.4) and hypertension (HR, 1.6; 95% CI, 1.2 to 2.2) were significantly associated with subsequent arterial events whereas previous venous event (HR, 2.6; 95% CI, 1.5 to 4.4) and age $65 years (HR, 1.7; 95% CI, 1.2 to 2.5) were significant predictors of future venous thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationTefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
Self-citationMyeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Self-citationTefferi, A., & Barbui, T. (2015) · American Journal of Hematology · doi:10.1002/ajh.23895 · Cited by 270
Self-citationHultcrantz, M., Björkholm, M., Dickman, P. W., Landgren, O., Derolf, Å. R., Kristinsson, S. Y., & Andersson, T. M. L. (2018) · Annals of Internal Medicine · doi:10.7326/m17-0028 · Cited by 268
Metadata
- Authors
- Barbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., Bertozzi, I., Casetti, I., Pardanani, A., Passamonti, F., Vannucchi, A. M., & Tefferi, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-11-06
- Volume
- 124
- Issue
- 19
- Pages
- 3021-3023
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2089993696
- Cited by
- 161
- References
- 0
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. https://app.cochat.ai/papers/10.1182/blood-2014-07-591610
- The paper
- Barbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., Bertozzi, I., Casetti, I., Pardanani, A., Passamonti, F., Vannucchi, A. M., & Tefferi, A. (2014). In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. https://doi.org/10.1182/blood-2014-07-591610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.